SPM Therapeutics is developing a new class of therapeutics based on natural MARESIN compounds that resolve inflammation at its source. Its patented lead candidate, MaR102-TL, is the first therapy designed specifically for vulvodynia. By targeting the root causes of inflammation, SPM Therapeutics aims to deliver safe, effective relief in an underserved therapeutic area.
